Welcome to Alumis Inc.’s Investor Conferences!
Investor Conference Schedule:
Morgan Stanley 22nd Annual Global Healthcare Conference
Thursday, September 5, 2024, 8:30 am ET
New York, NY
Format: fireside chat and one-on-one investor meetings
2024 Wells Fargo Healthcare Conference
Friday, September 6, 2024
Boston, MA
Format: one-on-one investor meetings only
Baird 2024 Global Healthcare Conference
Wednesday, September 11, 2024, 8:30 am ET
New York, NY
Format: presentation and one-on-one investor meetings; archived webcast replay on Investor Events page of Alumis website for 90 days following the conference
2024 Cantor Fitzgerald Global Healthcare Conference
Tuesday, September 17, 2024, 10:55 am ET
New York, NY
Format: fireside chat and one-on-one investor meetings; live webcast on Investor Events page of Alumis website, archived replay available for 90 days following the presentation
Stifel 2024 Immunology and Inflammation Virtual Summit
Wednesday, September 18, 2024, 10:00 am ET
Format: presentation
About Alumis: Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases.
How will this affect me?
As a potential investor, attending these conferences will provide you with valuable insights into Alumis Inc.’s innovative approach to developing oral therapies for immune-mediated diseases. You will have the opportunity to engage in one-on-one meetings with company management and hear from industry experts on the latest advancements in healthcare.
How will this affect the world?
Alumis Inc.’s participation in these investor conferences showcases their commitment to advancing healthcare solutions and improving patient outcomes on a global scale. By sharing their research and development efforts with a wider audience, Alumis is contributing to the growth and innovation of the biopharmaceutical industry, ultimately benefiting patients worldwide.
Conclusion:
Overall, Alumis Inc.’s presence at these upcoming investor conferences demonstrates their dedication to driving progress in the field of biopharmaceuticals and making a positive impact on both individuals and the global healthcare community.
